Importance of drug transporters in pharmacokinetics and drug safety

Toxicology Mechanisms and Methods

Volumn 18, Issue 1, 2008, Pages 1-10

  Ward, Peter ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Drug Elimination; Drug Drug Interactions; P glycoprotein; Pharmacokinetics; Pharmacology; Toxicity; Transporters

Indexed keywords

ABC TRANSPORTER; ADEFOVIR; AMPICILLIN; BREAST CANCER RESISTANCE PROTEIN; CAPTOPRIL; CARRIER PROTEIN; CATECHOLAMINE; CERIVASTATIN; CIMETIDINE; CISPLATIN; CYCLOSPORIN; DIGOXIN; DOXORUBICIN; ETOPOSIDE; FAMOTIDINE; FEXOFENADINE; GEMFIBROZIL; GLYCOPROTEIN P; INDINAVIR; METFORMIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PACLITAXEL; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; TOPOTECAN; UNINDEXED DRUG;

APICAL MEMBRANE; BASOLATERAL MEMBRANE; BLOOD BRAIN BARRIER; CHOLESTASIS; CYTOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INTERACTION; DRUG SAFETY; DRUG TRANSPORT; HUMAN; INTESTINE ABSORPTION; LIVER CLEARANCE; MEMBRANE PERMEABILITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; URINARY EXCRETION;

EID: 38549165867     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376510701795306     Document Type: Review

References (84)

1. Allen, J. D., Brinkhuis, R. F., Wijnholds, J., and Schinkel, A. H. 1999. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59:4237-4241.
2. Anzai, N., Kanai, Y., and Endou, H. 2006. Organic anion transporter family: current knowledge. J. Pharmacol. Sci. 100:411-426.
3. Backman, J. T., Kyrklund, C., Neuvonen, M., and Neuvonen, P. J. 2002. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72:685-691.
4. Badagnani, I., Castro, R. A., Taylor, T. R., Brett, C. M., Huang, C. C., Stryke, D., Kawamoto, M., Johns, S. J., Ferrin, T. E., Carlson, E. J., Burchard, E. G., and Giacomini, K. M. 2006. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 318:521-529.
5. Barendt, W. M., and Wright, S. H. 2002. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J. Biol. Chem. 277:22491-22496.
6. Beringer, P. M., and Slaughter, R. L. 2005. Transporters and their impact on drug disposition. Ann. Pharmacother. 39:1097-1108.
7. Bourdet, D. L., Pritchard, J. B., and Thakker, D. R. 2005. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther. 315:1288-1297.
8. Breedveld, P., Zelcer, N., Pluim, D., Sonmezer, O., Tibben, M. M., Beijnen, J. H., Schinkel, A. H., van Tellingen, O., Borst, P., and Schellens, J. H. 2004. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 64:5804-5811.
9. Breidert, T., Spitzenberger, F., Grundemann, D., and Schomig, E. 1998. Catecholamine transport by the organic cation transporter type 1 (OCT1). Br. J. Pharmacol. 125:218-224.
10. Bretschneider, B., Brandsch, M., and Neubert, R. 1999. Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm. Res. 16:55-61.
11. Brouwers, J. R., and de Smet, P. A. 1994. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet. 27:462-485.
12. Chen, A. Y., Yu, C., Potmesil, M., Wall, M. E., Wani, M. C., and Liu, L. F. 1991. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 51:6039-6044.
13. Chen, Z. S., Kawabe, T., Ono, M., Aoki, S., Sumizawa, T., Furukawa, T., Uchiumi, T., Wada, M., Kuwano, M., and Akiyama, S. I. 1999. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 56:1219-1228.
14. Choudhuri, S., and Klaassen, C. D. 2006. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25:231-259.
15. Cohen, S. M., Klaunig, J., Meek, M. E., Hill, R. N., Pastoor, T., Lehman-McKeeman, L., Bucher, J., Longfellow, D. G., Seed, J., Dellarco, V., Fenner-Crisp, P., and Patton, D. 2004. Evaluating the human relevance of chemically induced animal tumors. Toxicol. Sci. 78:181-186.
16. Conseil, G., Deeley, R. G., and Cole, S. P. 2005. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 15:523-533.
17. Cui, Y., Konig, J., Buchholz, J. K., Spring, H., Leier, I., and Keppler, D. 1999. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55:929-937.
18. Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., and Kim, R. B. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:866-871.
19. Deguchi, T., Takemoto, M., Uehara, N., Lindup, W. E., Suenaga, A., and Otagiri, M. 2005. Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. J. Pharmacol. Exp. Ther. 314:932-938.
20. Dixit, R., and Ward, P. 2006. Use of Classical Pharmacokinetic Evaluations in Drug Development and Safety Assessment Toxicokinetics and Risk Assessment, Lipscomb, J. C., and Ohanian, E. V., (Eds.), Informa Healthcare USA Inc.: New York, pp. 95-122.
21. Dringen, R., Hamprecht, B., and Broer, S. 1998. The peptide transporter PepT2 mediates the uptake of the glutathione precursor CysGly in astroglia-rich primary cultures. J. Neurochem. 71:388-393.
22. Food and Drug Administration. 2006. Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling.
23. Frenia, M. L., and Long, K. S. 1992. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann. Pharmacother. 26:234-237.
24. Hayer-Zillgen, M., Bruss, M., and Bonisch, H. 2002. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 136:829-836.
25. He, G., Massarella, J., and Ward, P. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-484.
26. He, W., Miao, F. J., Lin, D. C., Schwandner, R. T., Wang, Z., Gao, J., Chen, J. L., Tian, H., and Ling, L. 2004. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429:188-193.
27. Hebert, M. F., Dowling, A. L., Gierwatowski, C., Lin, Y. S., Edwards, K. L., Davis, C. L., Marsh, C. L., Schuetz, E. G., and Thummel, K. E. 2003. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13:661-674.
28. Herweijer, H., Sonneveld, P., Baas, F., and Nooter, K. 1990. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J. Natl. Cancer Inst. 82:1133-1140.
29. Hill, G., Cihlar, T., Oo, C., Ho, E. S., Prior, K., Wiltshire, H., Barrett, J., Liu, B., and Ward, P. 2002. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab. Dispos. 30:13-19.
30. Hirohashi, T., Suzuki, H., and Sugiyama, Y. 1999. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. 274:15181-15185.
31. Ho, E. S., Lin, D. C., Mendel, D. B., and Cihlar, T. 2000. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 11:383-393.
32. Ho, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., and Kim, R. B. 2006. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
33. Horio, M., Lovelace, E., Pastan, I., and Gottesman, M. M. 1991. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles. Biochim. Biophys. Acta 1061:106-110.
34. Hosoyamada, M., Sekine, T., Kanai, Y., and Endou, H. 1999. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276:F122-128.
35. Huisman, M. T., Smit, J. W., Crommentuyn, K. M., Zelcer, N., Wiltshire, H. R., Beijnen, J. H., and Schinkel, A. H. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids 16:2295-2301.
36. Inotsume, N., Nishimura, M., Nakano, M., Fujiyama, S., and Sato, T. 1990. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J. Clin. Pharmacol. 30:50-56.
37. Jariyawat, S., Sekine, T., Takeda, M., Apiwattanakul, N., Kanai, Y., Sophasan, S., and Endou, H. 1999. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J. Pharmacol. Exp. Ther. 290:672-677.
38. Jonker, J. W., Wagenaar, E., van Deemter, L., Gottschlich, R., Bender, H. M., Dasenbrock, J., and Schinkel, A. H. 1999. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br. J. Pharmacol. 127:43-50.
39. Juliano, R. L., and Ling, V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-162.
40. Kajosaari, L. I., Niemi, M., Neuvonen, M., Laitila, J., Neuvonen, P. J., and Backman, J. T. 2005. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 78:388-399.
41. Kedderis, G. L. 1997. Pharmacokinetics of drug interactions. Adv. Pharmacol. 43:189-203.
42. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., and Wilkinson, G. R. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294.
43. Kimchi-Sarfaty, C., Oh, J. M., Kim, I. W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., and Gottesman, M. M. 2007. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528.
44. Kool, M., Van Der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., Scheper, R. J., Elferink, R. P., Baas, F., and Borst, P. 1999. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U S A 96:6914-6919.
45. Kruh, G. D., and Belinsky, M. G. 2003. The MRP family of drug efflux pumps. Oncogene 22:7537-7552.
46. Lacy, S. A., Hitchcock, M. J., Lee, W. A., Tellier, P., and Cundy, K. C. 1998. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci. 44:97-106.
47. Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., and Dey, S. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
48. Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G., Leake, B. F., and Kim, R. B. 2005. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280:9610-9617.
49. Mahar Doan, K. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., and Polli, J. W. 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303:1029-1037.
50. Maliepaard, M., van Gastelen, M. A., Tohgo, A., Hausheer, F. H., van Waardenburg, R. C., de Jong, L. A., Pluim, D., Beijnen, J. H., and Schellens, J. H. 2001. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res. 7:935-941.
51. Markovich, D., and Murer, H. 2004. The SLC13 gene family of sodium sulphate/carboxylate cotransporters. Pflugers Arch. 447:594-602.
52. Matter, K., and Balda, M. S. 2003. Functional analysis of tight junctions. Methods 30:228-234.
53. Meek, M. E., Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., Longfellow, D. G., Pastoor, T., Seed, J., and Patton, D. E. 2003. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33:591-653.
54. Mita, S., Suzuki, H., Akita, H., Hayashi, H., Onuki, R., Hofmann, A. F., and Sugiyama, Y. 2006. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab. Dispos. 34:1575-1581.
55. Morrow, C. S., Smitherman, P. K., and Townsend, A. J. 2000. Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol. Carcinog. 29:170-178.
56. Motohashi, H., Uwai, Y., Hiramoto, K., Okuda, M., and Inui, K. 2004. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur. J. Pharmacol. 503:25-30.
57. Muck, W., Mai, I., Fritsche, L., Ochmann, K., Rohde, G., Unger, S., Johne, A., Bauer, S., Budde, K., Roots, I., Neumayer, H. H., and Kuhlmann, J. 1999. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther. 65:251-261.
58. Najjar, T. A., Abou-Auda, H. S., and Ghilzai, N. M. 1998. Influence of piperacillin on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. Cancer Chemother. Pharmacol. 42:423-428.
59. Seithel, A., Eberl, S., Singer, K., Auge, D., Heinkele, G., Wolf, N. B., Dorje, F., Fromm, M. F., and Konig, J. 2007. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 35:779-786.
60. Servais, A., Lechat, P., Zahr, N., Urien, S., Aymard, G., Jaudon, M. C., Deray, G., and Isnard Bagnis, C. 2006. Tubular transporters and clearance of adefovir. Eur. J. Pharmacol. 540:168-174.
61. Shimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H., and Sugiyama, Y. 2005. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33:1477-1481.
62. Shitara, Y., Hirano, M., Sato, H., and Sugiyama, Y. 2004. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311:228-236.
63. Shitara, Y., Horie, T., and Sugiyama, Y. 2006. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27:425-446.
64. Shitara, Y., Sato, H., and Sugiyama, Y. 2005. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45:689-723.
65. Simonson, S. G., Raza, A., Martin, P. D., Mitchell, P. D., Jarcho, J. A., Brown, C. D., Windass, A. S., and Schneck, D. W. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76:167-177.
66. Sorrentino, B. P., Brandt, S. J., Bodine, D., Gottesman, M., Pastan, I., Cline, A., and Nienhuis, A. W. 1992. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257:99-103.
67. Sun, W., Wu, R. R., van Poelje, P. D., and Erion, M. D. 2001. Isolation of a family of organic anion transporters from human liver and kidney. Biochem. Biophys. Res. Commun. 283:417-422.
68. Sweet, D. H., Miller, D. S., Pritchard, J. B., Fujiwara, Y., Beier, D. R., and Nigam, S. K. 2002. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. 277:26934-26943.
69. Tahara, H., Kusuhara, H., Endou, H., Koepsell, H., Imaoka, T., Fuse, E., and Sugiyama, Y. 2005. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 315:337-345.
70. Taipalensuu, J., Tornblom, H., Lindberg, G., Einarsson, C., Sjoqvist, F., Melhus, H., Garberg, P., Sjostrom, B., Lundgren, B., and Artursson, P. 2001. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299:164-170.
71. Takeda, M., Babu, E., Narikawa, S., and Endou, H. 2002. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur. J. Pharmacol. 438:137-142.
72. Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T., and Hori, R. 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263:840-845.
73. Tian, X., Zamek-Gliszczynski, M. J., Zhang, P., and Brouwer, K. L. 2004. Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol. Pharmacol. 66:1004-1010.
74. Treiber, A., Schneiter, R., Delahaye, S., and Clozel, M. 2004. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J. Pharmacol. Exp. Ther. 308:1121-1129.
75. Troutman, M. D., and Thakker, D. R. 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 20:1200-1209.
76. Tsujimoto, M., Hirata, S., Dan, Y., Ohtani, H., and Sawada, Y. 2006. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab. Pharmacokinet.165-169.
77. Wang, D. S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., and Sugiyama, Y. 2002. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302:510-515.
78. Wang, J. S., Ruan, Y., Taylor, R. M., Donovan, J. L., Markowitz, J. S., and DeVane, C. L. 2004. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. 7:415-419.
79. Wong, H., Lehman-McKeeman, L. D., Grubb, M. F., Grossman, S. J., Bhaskaran, V. M., Solon, E. G., Shen, H. S., Gerson, R. J., Car, B. D., Zhao, B., and Gemzik, B. 2005. Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. 84:232-242.
80. Yamazaki, M., Akiyama, S., Nishigaki, R., and Sugiyama, Y. 1996. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm. Res. 13:1559-1564.
81. Yanase, K., Tsukahara, S., Asada, S., Ishikawa, E., Imai, Y., and Sugimoto, Y. 2004. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. 3:1119-1125.
82. Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., and Inui, K. 2006. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 319:879-886.
83. Zeng, H., Bain, L. J., Belinsky, M. G., and Kruh, G. D. 1999. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 59:5964-5967.
84. Zeng, H., Liu, G., Rea, P. A., and Kruh, G. D. 2000. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 60:4779-4784.